Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage ...

With historical data showing migraine to be underdiagnosed and undertreated, new guidance from the American College of ...

Attention-deficit hyperactivity disorder (ADHD) is a well-known neurodevelopmental disorder that affects the brain's ability ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

Centre, a national research platform led by Nanyang Technological University, Singapore's (NTU Singapore) Lee Kong Chian School of Medicine (LKCMedicine), will lead a multi-institutional research ...

Early treatment will prevent the condition from getting worse. Keep in regular contact with your doctor following a diagnosis of COPD. Reach out if you experience side effects of medications ...

PT-00114 is under clinical development by Protagenic Therapeutics and currently in Phase II for Treatment Resistant Depression. According to GlobalData, Phase II drugs for Treatment Resistant ...

The success of Dupixent has demonstrated the viability of biologics in COPD ... a new treatment paradigm, targeting specific inflammatory pathways to reduce exacerbations and improve patient ...

COPD exacerbations can be life threatening. Learn more about COPD and its different stages. Regular use of spirometry for COPD progression tracking is important for COPD treatment. Each stage ...

All randomized, double-blind, placebo- controlled trials evaluating the efficacy of systemic corticosteroids in COPD exacerbations were identified. Trials that randomized patients to nebulized ...